China’s pharmaceutical R&D demand recovers, while diagnostics and surgical robots remain constrained by pricing
Nomura sees a continued recovery in China’s upstream life sciences demand in multinational healthcare companies’ third-quarter results. However, the operating performance of innovative drugs, diagnostics and surgical robots diverges, and pricing reforms continue to affect revenue realization.
Nomura ·